Your paper 'Transcriptome and genome sequencing uncovers functional variation in humans' has been scheduled for Advance Online Publication (AOP) on http://www.nature.com/nature on 15 September 2013 at 1800 London time / 1300 US Eastern Time. The embargo will lift at this time. Please forward this information to any co-authors.
Papers published online before they have been allocated to a print issue will be citable via a digital object identifier (DOI) number. The DOI for your paper will be 10.1038/nature12531. Once the paper is published electronically, the DOI can be used to retrieve the abstract and full text from the Nature web site (abstracts are available to everyone, full text only to subscribers) by adding it to the following URL: http://dx.doi.org/ .
On the Tuesday before publication, Nature distributes a press release highlighting papers of general interest. Journalists are given the name of the author(s) to contact, together with phone numbers and e-mail addresses. Journalists are also given online access not only to the papers on the press release but to all the papers due to appear in that issue. This means that your work could well receive media interest even if not featured on the press release, so it would be helpful if you (as corresponding author, we would, as a matter of course, put your name and affiliation on our press release as a contact, and attribute the work to you plus colleagues, so please let me know if this would not be appropriate) or a colleague could be available to answer any inquiries in the days leading up to publication.
You are free to discuss your paper with the media, but we ask you to do this no more than five days before the publication date, and to ensure that Nature's embargo conditions are understood by journalists and others. Nature reserves the right to halt the publication of a paper if these conditions are broken. Journalists are permitted to show papers to independent specialists a few days in advance of publication, under embargo conditions, solely for the purpose of commenting on the work described.
Wire services stories must always carry the embargo time at the head of each item, and may not be sent out more than 24 hours before that time.
Journalists should credit Nature as the source of stories covered.
If you need further clarification about anything related to publicity, please contact one of the Nature offices, as indicated below:
For North America and Canada
Neda Afsarmanesh (Nature, New York)
Tel: +1 212 726 9231; E-mail:
n.afsarmanesh@us.nature.com
For Japan, Korea, China, Singapore and Taiwan
Eiji Matsuda (Nature, Tokyo)
Tel: +81 3 3267 8751; E-mail:
e.matsuda@natureasia.com
For the UK
Rebecca Walton (Nature, London)
Tel: +44 20 7843 4502; E-mail:
r.walton@nature.com
Rachel Twinn (Nature, London)
Tel: +44 20 7843 4658; E-mail:
r.twinn@nature.com
If you are reporting sequence or structural data with an accession code for a public database, we request you to set the release into the public domain upon receipt of this letter. This will allow our editors to test the link from the journal website to the database in readiness for the date of publication of your article. For authors reporting protein structures, release of the coordinates now will also allow us to set up a three-dimensional view window within the online version of the article.
For any queries concerning proofs or corrections, please contact the Editorial Production department in London.
You and your coauthors, or your institutions, can also order copies of the issue of Nature containing your article: please contact g.painter@nature.com, stating the publication reference and the number of copies required.
If you and your coauthors are not subscribers to Nature and would like to subscribe, please contact subscriptions@nature.com and ask for details of special prices for published Nature authors.
Dear all,
It is my great pleasure to tell you that the Geuvadis RNAseq paper has been accepted in Nature!
Needless to say, I'm extremely happy to finally be at this point, and to be able to thank all of you for your contributions. We wouldn't be here without the hard work from all of you, the huge pool of scientific expertise and insight, and the collaborative spirit that we've had in this project. Please pass my thanks also to technicians and other members of your lab who contributed to this work.
It was a really enjoyable experience to work with all of you, and I hope that this will inspire many other collaborations amongst us. I had a lot of fun and I hope you did too! But the most important thing is that I think we can all be proud of the outcome. It's a great paper and a great data set that make an important contribution to the field.
We're now going through some final formatting edits, and we'll be in touch about press releases, publication and embargo dates, etc. when we know more. Feel free to share the news with close colleagues, but please don't advertise this yet in the public domain such as social media. The companions papers are in a good shape too: we're waiting for the final confirmation of the acceptance of the QC paper in Nature Biotechnology so more good news will follow, and the splicing paper is under review in Genome Research.
best regards,
Tuuli
PS. Please note that my University of Geneva email address will not work for much longer (in case you didn't know, I'm spending this year at Stanford). Please use tuuli.e.lappalainen@gmail.com for future correspondence.
-- Tuuli Lappalainen, PhD Department of Genetics, Stanford University School of Medicine Email: tuuli.e.lappalainen@gmail.com Tel: +1 415 351 9713 Bustamante lab Department of Genetics 300 Pasteur Dr. Lane L301 Stanford, CA 94305-5120 USA